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Introduction
Coronary artery disease (CAD) starts with the formation of
atherosclerotic plaques in the coronary arteries. Abrupt occlusion
of these atherosclerotic arteries due mainly to thrombosis leads
to coronary heart diseases: unstable angina, acute myocardial
infarction and sudden death (1). CAD is a disease of several
risk factors, most notably among which are hyperlipidemia,
hypertension, diabetes mellitus and tobacco smoking. Multiple
pathogenic factors are known to be operating at the cellular
level, such as enhanced oxidation of low-density lipoprotein
(LDL) and proliferation of monocyte-derived macrophages
and smooth muscle cells (SMCs). Atherogenesis is a complex
process involving, among others, endothelial cell dysfunction
such as increased endothelial permeability to lipoproteins.
Such dysfunction is mediated by many factors such as nitric
oxide (NO), platelet-derived growth factor (PDGF), prosta-
cyclin, angiotensin II and endothelin. It also involves upregu-
lation of endothelial adhesion molecules such as vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1) and selectins. Inflammatory processes
underlying atherogenesis have been the focus of intense
studies, as migration of leukocytes and monocytes–macroph-
ages is demonstrated in the subendothelial space (2–4).
Atherosclerotic lesions first appear as deposits of lipid in the
intima of large muscular and elastic arteries, which then
progress through several stages before clinical manifestations
of CAD emerge (5). Thus, abnormal lipid metabolism remains
the crux of the pathogenesis of CAD, on which inflammatory
and other mechanisms superimpose (6–8).
Several approaches have been proposed to counter progress
of atherosclerosis: reduction of the risk factors, use of statins,
 -blockers, angiotensin-converting enzyme (ACE) inhibitors,
antithrombotic drugs and proper use of estrogen and antioxi-
dants (9–11). However, there still seems no consensus as to the
best pharmacological option to control atherosclerosis.
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Ayurvedic medicine is a time-tested system of medicine which has been in clinical use for centuries in
India. Being a time-tested system, it has an edge over other existing systems of health management,
especially for dealing with chronic disorders such as coronary artery disease, which is of a complex
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factors related to atherosclerosis, a combination drug has been
developed as BHUx. It is a patented polyherbal formulation
(12), simultaneously targeting oxidative stress and inflamma-
tion (13). It consists of a specific water-soluble extract of
five medicinal plants, which are time tested and have been
used in the ayurvedic system of medicine for many centuries
(14). These plants are: Commiphora mukul (Hook. Ex Stock,
Burseraceae) synonym: Balsamodendron mukul (15),
Terminalia arjuna (W& A, Comberetaceae) (16), Boswellia
serrata Roxb (Burseraceae) (17), Semecarpus anacardium
Linn.f. (Anacardiaceae) (18) and Strychnos nux vomica Linn.
(Loganiaceae) (19) in a particular ratio. CaCO3 (Shankha
Bhasma) has been added to the finished product to reduce gas-
tric irritation, if any. The finished product has been standardized
by using high-performance liquid chromatography (HPLC)
and thin-layer chromatography (TLC) fingerprinting (13).
These plants contain several phytochemicals, which may tar-
get several signaling pathways at the same time and may bring
about benefits through a synergistic or additive action (20). In
the present experiment, BHUx was orally given for 3 months
to rabbits pre-treated with an atherogenic diet for 3 months.
After 6 months, all the animals were sacrificed for histological
study. The results of the groups each consisting of six animals
were compared. It is demonstrated that BHUx significantly
reduced intimal thickening and calcium deposition, and stabi-
lized the collagen cap in the plaque in the dorsal aorta.
Methods
Materials
All the chemicals of AR grade were purchased from Merck
and Central Drug House, Delhi. Male inbred albino rabbits of
nearly the same age (60 days old) and weight (1.3 kg average)
were from the central animal house of the Institute of Medical
Sciences. The Institute’s ethical committee for animal welfare
approved the experimental protocol.
Preparation of BHUx
All the plants were purchased from the Surya Pharmaceuticals,
D-17 Industrial area, Ramnagar, Varanasi (lot number
1992/4–8) and their authenticity was confirmed as per the
standards given in the Indian Pharmacopoeia. They were also
verified physically with the standard specimens kept in the
museum of the Department of Dravyaguna, Faculty of Ayurveda.
The samples of the plant materials used were preserved in the
Department Herbarium as voucher # MC-Y-18 to 22 for future
records. The aqueous extract of each medicinal plant was pre-
pared separately as described in the Ayurvedic text (14) with
special modifications (patented, 12). They were mixed in a
particular ratio and dried at 46 C to produce a homogeneous
powder. TLC and HPLC fingerprinting of each batch was car-
ried out and maintained throughout the experiment, to avoid
batch-to-batch variations (13). For biological experiments,
BHUx was suspended in double-distilled water with 15% gum
acacia and given orally.
Experiments with Albino Rabbits
After 1 week of acclimatization, rabbits were divided into two
groups. One group was kept on the normal control diet and the
other group was subjected to the atherogenic diet (40 g/day per
animal) for 3 months along with added normal diet and water
at libitum. Later on, the animals were randomly divided again
into two groups. One group was the experimental sham control
group, where animals were continued on the atherogenic diet
schedule, along with drug vector (15% gum acacia), while the
other group was the drug-treated experimental group where the
animals were given BHUx (600 mg/kg body weight) along
with the atherogenic diet for another 3 months. The number of
animals in each group was 10. After 6 months, all the surviv-
ing animals were sacrificed and the heart and complete aortic
tree were collected for histological study using standard oper-
ating procedures (21). In brief, tissues were dehydrated and
wax blocks were prepared. Serial microsections of 5  m thick-
nesses were cut out and divided into three groups. One group
was processed for normal hematoxylin and eosin (H&E) stain-
ing and the remaining two groups were stained with Van-G for
collagen content and with Alizarin red-S for calcium content
visualization.
Statistical Analysis
Data were analyzed by using Student’s t-test and analysis of
variance.
Results
BHUx Inhibits Plaque Formation and Improves
Survival
A significant reduction in the intimal thickening of the dorsal
aorta was demonstrated in the drug-treated animals compared
with the sham controls (H&E stain; Fig. 1A and B). The
BHUx-treated animals were further shown to have more colla-
gen content on the surface of the endothelium (Fig. 1C and D
stained by Van-G) and less deposition of calcium in the arterial
wall (Fig. 1E and F stained by Alizarin red-S). The overall sur-
vival rate of BHUx-treated animals was significantly higher
(70–80%) than that of the control animals (35–50%) (Fig. 2).
Discussion
Complex cellular mechanisms contribute to atherogeneis,
including SMC migration [stimulated by PDGF and trans-
forming growth factor (TGF)- ], T-cell activation [mediated
by tumor necrosis factoe (TNF)-  and interleukin (IL)-2], for-
mation of foam cells [from macrophages mediated by oxidized
LDL, macrophage colony-stimulating factor (M-CSF), TNF- 
and IL-1) and platelet adherence and aggregation (stimulated
by thromboxane A2, tissue factors, etc.) (22).
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As seen in the Results, BHUx remarkably prevented the for-
mation of thickened intima loaded heavily with fatty vacuoles
in the rabbits fed with the atherogenic diet. Several mechanisms
can explain this effect. It may be due to the reduced formation
of foam cells or induction of their apoptosis, or both. Another
possibility could be its inhibitory effect on M-CSF, which is
essential for viability and sustained growth of macrophages,
embedded in the endothelium (4). Inhibition of proliferation of
vascular SMCs and their migration to the intima is also possi-
ble (7). The inhibition of intimal thickening by BHUx may also
be explained by its antioxidant and anti-inflammatory properties
as shown in the case of probucol (11). BHUx has been shown
to inhibit lipid peroxidation induced by cumene hydro peroxide
and the activity of lipoxygenase-15 (responsible for LDL
oxidation) in different experimental systems (13).
The histological sections from the control animals showed a
very thin collagen cap on the inner surface of the plaque when
stained with Van-G, while this cap was intact in the BHUx-
treated animals. Matrix metalloproteinase (MMP) activation is
one of the significant factors for dissolving this protective
covering (23), leading to unstable atherosclerotic plaques.
The ratio of lipid core to fibrous content (determined by the
balance between SMC proliferation and extracellular matrix
synthesis stabilizing the plaque, and macrophages which
degrade collagen) is also important to determine the plaque vul-
nerability (24). Loss of the matrix-synthesizing SMCs is another
possibility for a weak fibrous cap, because caps of ruptured
coronary plaques contain a reduced number of SMCs. (25).
Current therapies to manage atherosclerosis are focused
predominantly on the stabilization of plaques rather than their
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Figure 1. (A and B) Effect of BHUx on the intimal thickening in albino rabbits. (A) A rabbit on the atherogenic diet for 6 months (sham control). (B) A rabbit
receiving BHUx 600 mg/kg body weight (last 3 months) along with the atherogenic diet (6 months). (C and D) Effect of BHUx on the collagen cap on the sur-
face of the plaque in the dorsal aorta in albino rabbits. (C) A rabbit on the atherogenic diet for 6 months (sham control). (D) A rabbit receiving BHUx 600 mg/kg
body weight (last 3 months) along with the atherogenic diet (6 months). (E and F) Effect of BHUx on the calcium deposition on the intima medial interface in
the dorsal aorta in albino rabbits. (E) A rabbit on the atherogenic diet for 6 months (sham control). (F) A rabbit receiving BHUx 600 mg/kg body weight (last
3 months) along with the atherogenic diet (6 months).regression. It is assumed that the reduced frequency of acute
vaso-occlusive events observed with interventions aimed to
modify lipid and other risk factors is at least partially
explained by the stabilization of plaques through alteration of
the plaque composition or by inhibition of the release of
MMPs and other proteases from mast cells (26). The potential
mechanisms of this benefit include improvement in endothelial
function and vasomotion, reduction of platelet aggregability
and thrombus formation, fibrinolytic and antioxidant activity,
as well as reduction of inflammation within plaques, reduced
matrix degradation due to inhibition of macrophage MMP
production and increasing collagen content. It is interesting to
point out that ACE inhibitor therapy has been shown to reduce
the risk of myocardial infarction and stroke by upregulating
collagen synthesis (27). The prominent collagen cap seen in
the BHUx-treated animals could be due to its anti-inflamma-
tory effects, as the agent has been shown to exhibit significant
inhibition of cyclooxygenase-2 activity and possess antioxi-
dant activity (13), One of its components, S.anacardium, has
also been shown to inhibit lipopolysaccharide (LPS)-induced
NO production from activated peritoneal macrophages (28).
We have shown in the histological sections a significant
reduction of calcium content in the dorsal aorta from the
BHUx-treated animals compared with the control animals, in
which a high degree of calcification both on the surface and
within the plaque was observed when stained with Alizarin
red-S. Vascular calcification is highly correlated with cardio-
vascular disease mortality, especially in patients with diabetes.
Recent studies have shown that chemical composition and
morphology, rather than anatomy (degree of stenosis), of
atherosclerotic plaques determine their instability and predict
disease progression (29). The increase in calcification is also
associated with hyperlipidemia and elevated pH through alter-
ation in the ratios of bicarbonate/CO2 (30).
Deposition of cholesterol and calcium on the elastic fiber,
resulting in decreased elastin synthesis and cross-link formation,
is directly related to calcification in SMCs. It is also reported that
M-CSF is one of the important factors for arterial calcification,
as it maintains the balance of osteoclasts with the osteoblasts,
which are differentiated from the arterial SMCs (31).
Calcium antagonists have been one of the most relevant
therapeutic tools for patients with hypertension, and their
effects on calcium transport may influence the cellular changes
leading to atherosclerosis (32). Calcification in arteriosclerosis
is also inhibited by antioxidants, as aged garlic extract (AGE)
and green tea have been shown to reduce arterial calcification
through their antioxidant properties (33,34). Thus, we suggest
that the BHUx-mediated reduction in the calcium content in
the atherosclerotic plaque could also be attributed to its antiox-
idant property or to the calcium channel blocking property
of T.arjuna (a component of BHUx) (35). It could also be
explained by the modulation of the inflammatory cascade
through the action of S.anacardium (28). Furthermore, the
effect of BHUx may be exerted through downregulation of M-
CSF, because it reduces calcification and intimal thickening
without affecting the level of blood cholesterol (4).
We would like to emphasize that BHUx significantly
enhanced the overall survival of animals (70–80%) as compared
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Figure 2. Effect of BHUx on the survival rate of rabbits kept on the atherogenic diet and BHUx treatment for 6 months. (1) Rabbits on a normal diet; (2) rabbits
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with the sham controls where survival was only 35–50% after
3 months of atherogenic diet administration.
We conclude that BHUx is capable of reducing the progress
of atherosclerosis, possibly through its anti-inflammatory, cal-
cium channel-modulatory and antioxidant properties. Further
studies are warranted to test these claims in the clinical setting.
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